Kymera IPO Presentation Deck

CANCER FIBROSIS Solid Tumors KYMERA Autoimmune Fibrosis PD-L1 mRNA Levels (% Control) PD-L1 Downregulation PD-L1 mRNA in SU-DHL-1 cells PD-L1 mRNA in SUP-M2 cells 150 125- 100 75 STAT3 Degradation in Tumor Microenvironment 50- 2 3 Log [STAT3 Degrader] (nM) Treatment of cells with Kymera's STAT3 degrader reduced transcription of PD-L1 mRNA STAT3 degradation may reverse a key tumor intrinsic mechanism for immune suppression Increased Inflammation in Tumor Associated Immune Cells Log2-Fold Change STAT 3 Degrader vs DMSO Immune Markers CD1B TLR8 LILRA1- LILR82- IL21R- FCGR2A S100A12- $100A8 CD14- MSAASA CD163 STODAS IL-6: 1hr 6hr Signaling Cytokines Survival/Proliferation CCL25 CSF1 TNF- ICOSLG- IL23A- IL17A- CCR7- TMEM173- CXCL1- JAK3- SERPINA2 IL10 CXCL13 IL-6: 1hr 6hr IRF8 NOTCHI MYC AREG IL-6: 1hr 6hr STAT3 degrader blocked IL-6-induced increases in gene expression in hPBMC Data suggest degradation of STAT3 reverses expression of genes contributing to immune suppression

View entire presentation